Intercept Pharmaceuticals, based in Morristown, New Jersey, is laying off 146 employees in three tranches starting December 31, 2025, extending through June 2026. The layoffs follow the company's withdrawal of Ocaliva from the U.S. market in November 2025 after FDA concerns about clinical benefits